Sanofi Consumer Healthcare India (NSE:SANOFICONR) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SANOFICONR Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
22 GF Score
Price ₹4,222.10
! 2 Warning Signs
View Full Analysis

What is Sanofi Consumer Healthcare India Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sanofi Consumer Healthcare India is: No Data: Cannot be evaluated.

Sanofi Consumer Healthcare India  (NSE:SANOFICONR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sanofi Consumer Healthcare India Risk Assessment Related Terms

NSE:SANOFICONR vs LLY, JNJ, ABBV: Risk Assessment Comparison

For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi Consumer Healthcare India Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sanofi Consumer Healthcare India's Risk Assessment falls into.


NSE:SANOFICONR
22GF Score
Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Consumer Healthcare India Business Description

Other Exchanges 544250:India
Address Pirojshanagar, Eastern Express Highway, Unit 1104, 11th Floor, Godrej Two, Vikhroli East, Mumbai, MH, IND, 400079
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
22GF Score

Get the complete analysis for NSE:SANOFICONR

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,222.10
Price